Boehringer Ingelheim, Teva, et al Settle EPP Claims for $54 Million

The court granted preliminary approval over a settlement agreement involving a class of end-payor plaintiffs in the amount of $54 million because the agreement was substantively and procedurally fair. “The Court finds that the proposed settlement, which includes a cash payment of $54,000,000 by Defendants into an escrow account for the benefit of the Class . . . in exchange for, inter alia, dismissal of the litigation between Indirect Purchaser Class Plaintiffs and Defendants with prejudice and releases of certain claims filed or that could have been filed against Defendants by Indirect Purchaser Class Plaintiffs and the Class . . . was arrived at by arm’s-length negotiations by highly experienced counsel after years of litigation, [and] falls within the range of possibly approvable settlements . . . .”

In re Aggrenox Antitrust Litigation, 3-14-md-02516 (CTD 2018-03-06, Order) (Stefan R. Underhill)

2018-03-09T15:08:02+00:00 March 9th, 2018|Antitrust, Docket Report|